Cargando…
Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159539/ http://dx.doi.org/10.1016/S0169-5002(21)00241-5 |